Stock listing

gettex:10V Immunic, Inc. Aktie

German listing (gettex) of Immunic, Inc. · home listing NASDAQ:IMUX

Follow Immunic, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:IMUX

$6.99 USD -0.53 (-7.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:IMUX

Past year +1.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.97 – $7.56 USDNov 20, 2026
Volume
295,908 sharesNov 20, 2026
Market cap
$95.37M USDAt the close on Nov 20, 2026 · price × 13.64M shares outstanding
52-week range
$5.06 – $17.43 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.22M USDMedian day 316,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Immunic, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IMUX · Home$6.99 USD-0.53 (-7.0%)295,908$7.31$7.56$6.97$7.52Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMUX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.99-0.53-7.0%$7.31$7.56$6.97295,908
$7.52+0.19+2.6%$7.32$7.74$7.32174,721
$7.33+0.10+1.4%$7.26$7.475$7.06141,197
$7.23-0.29-3.9%$7.51$7.828$7.21171,069
$7.52-0.27-3.5%$7.87$7.87$7.52105,144
$7.79-0.33-4.1%$7.95$8.106$7.50218,938
$8.12+0.08+1.0%$8.20$8.42$8.08156,857
$8.04+0.08+1.0%$7.89$8.14$7.73198,112
$7.96+0.21+2.7%$7.885$8.22$7.553260,223
$7.75+0.43+5.9%$7.40$7.88$7.34179,666
$7.32-0.62-7.8%$7.97$8.065$7.21263,038
$7.94+0.34+4.5%$7.78$8.00$7.49175,684
$7.60+0.26+3.5%$7.38$7.87$7.35166,969
$7.34-0.17-2.3%$7.68$7.85$7.16276,573
$7.51-0.285-3.7%$7.70$7.78$7.37244,096
$7.795-0.185-2.3%$7.99$8.22$7.60201,540
$7.98+0.37+4.9%$7.60$8.196$7.56258,164
$7.61+0.33+4.5%$7.32$7.73$7.31356,175
$7.28-0.13-1.8%$7.36$7.505$7.06432,286
$7.41+0.19+2.6%$7.41$7.44$6.995367,126
$7.22-0.26-3.5%$7.50$7.70$7.16473,400
$7.48+0.07+0.9%$7.44$7.85$7.41329,800
$7.41+0.42+6.0%$6.99$7.64$6.95429,600
$6.99+0.02+0.3%$6.97$7.285$6.81319,800
$6.97-0.13-1.8%$7.10$7.92$6.80366,200
$7.10+0.44+6.6%$6.64$7.14$6.59285,100
$6.66-0.23-3.3%$6.78$7.035$6.35438,000
$6.89-1.06-13.3%$7.96$8.14$6.825572,800
$7.95-0.24-2.9%$8.19$8.444$7.92152,100
$8.19+0.63+8.3%$7.63$8.60$7.47510,900
$7.56-0.07-0.9%$7.65$7.65$7.25588,800
$7.63-0.19-2.4%$7.80$7.899$7.49381,200
$7.82-0.25-3.1%$8.13$8.17$7.77347,800
$8.07+0.11+1.4%$8.00$8.17$7.70490,200
$7.96-0.68-7.9%$8.69$8.87$7.755723,000
$8.64-0.66-7.1%$9.30$9.467$8.60557,700
$9.30+0.39+4.4%$9.00$9.44$8.74448,500
$8.91-0.60-6.3%$9.60$9.63$8.87435,000
$9.51+0.165+1.8%$9.32$9.935$9.09660,400
$9.345+0.025+0.3%$9.42$9.50$9.12316,600
$9.32-0.05-0.5%$9.32$9.535$9.09448,400
$9.37-1.47-13.6%$10.85$11.12$9.36660,600
$10.84+0.01+0.1%$10.95$11.28$10.76430,500
$10.83+0.21+2.0%$10.86$11.07$10.47468,600
$10.62+0.27+2.6%$10.30$10.74$10.21403,600
$10.35+0.23+2.3%$10.38$10.50$10.10578,900
$10.12-0.25-2.4%$10.50$10.63$10.03229,300
$10.37-0.86-7.7%$11.19$11.27$10.30287,300
$11.23-0.19-1.7%$11.43$11.46$11.04251,400
$11.42-0.42-3.5%$11.93$11.95$11.24332,700
$11.84-0.35-2.9%$12.05$12.32$11.73295,100
$12.19-0.55-4.3%$12.72$12.99$11.99352,800
$12.74-0.37-2.8%$12.93$13.28$12.35405,000
$13.11+0.35+2.7%$12.77$13.17$12.44420,900
$12.76-1.48-10.4%$14.24$14.92$11.56841,600
$14.24-0.34-2.3%$14.70$15.22$14.10225,100
$14.58-1.22-7.7%$16.05$16.10$14.58229,200
$15.80+0.40+2.6%$15.39$16.00$15.19124,800
$15.40-0.90-5.5%$16.21$16.30$15.00357,900
$16.30-0.19-1.2%$16.49$16.70$16.10162,900
$16.49+0.07+0.4%$16.34$16.66$15.80240,200
$16.42-0.04-0.2%$16.50$17.18$16.15231,100
$16.46-0.04-0.2%$16.48$16.83$16.06140,100
$16.50+0.40+2.5%$16.22$16.83$16.20147,700
$16.10-0.35-2.1%$16.39$16.67$15.92200,600

Splits

2 splits since 2019 · NASDAQ:IMUX · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-40Consolidation
Ticker
gettex:10V
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Latest news

All Immunic, Inc. news

Immunic, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
32 in the last 12 months · 207 in all · newest Nov 13, 2026 · oldest 2019
Calls
13 calls with a replay · 13 with a transcript · latest Nov 7, 2024
Decks
78 decks · latest Nov 5, 2026

Where Immunic, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IMUX · Home listingNASDAQUnited StatesUSD
BOATS:IMUXBOATSUnited StatesUSD
Frankfurt:10VFrankfurtGermanyEUR
gettex:10V · This pagegettexGermanyEUR
LS Exchange:A428WYLS ExchangeGermanyEUR
Tradegate:10VTradegateGermanyEUR
Lang & Schwarz:A428WYLang & SchwarzGermanyEUR
Munich:10VMunichGermanyEUR

Valuation

Price/book 0.9× against a median of 3.2×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$36.09M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.51

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Immunic, Inc. · NASDAQ:IMUXUS$95.37M−US$36.09Mn/an/an/a0.9×n/a0.0×1.51
Unicycive Therapeutics, Inc. · NASDAQ:UNCYUS$97.77MUS$39.32Mn/an/an/a1.9×n/a0.0×1.09
NovaBridge Biosciences · NASDAQ:NBPUS$96.28MUS$68.37Mn/an/an/a3.2×n/a0.0×1.37
Wuhan YZY Biopharma Co., Ltd. Class H · HKEX:2496US$96.16MUS$105.5Mn/a7.9×n/an/a−53.2%n/an/a
PDS Biotechnology Corporation · NASDAQ:PDSBUS$95.39MUS$80.15Mn/an/an/a7.1×n/a0.0×2.04
NRX Pharmaceuticals, Inc. · NASDAQ:NRXPUS$95.31MUS$76.46Mn/a17.7×n/an/a−458.5%n/a2.23
Allergy Therapeutics plc · LSE:AGYUS$95.27MUS$117.1Mn/a1.6×n/a17.1×−72.9%6.3×n/a
Voyager Therapeutics, Inc. · NASDAQ:VYGRUS$95.21M−US$11.60Mn/a−0.5×n/a0.7×−416.3%0.0×1.45
Outlook Therapeutics, Inc. · NASDAQ:OTLKUS$94.94MUS$83.70Mn/an/an/an/an/an/a1.10
Molecular Partners AG · SIX:MOLNUS$93.53M−US$4.92Mn/an/an/a1.0×n/a0.0×n/a
Sunhawk Vision Biotech, Inc. · TPEX:7759US$93.06MUS$82.44Mn/an/an/a7.3×n/a0.0×n/a
Median of the othersUS$95.29MUS$78.30M4.8×3.2×−244.6%0.0×1.41

Forecasts

13 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
42.64 USD · Analysts' mean
EPS, year to Dec 2026
-3.60 · 12 analysts

Team and board

Officers

OfficerRole
Erik LundgrenChief Executive Officer, Director
Glenn WhaleyChief Financial Officer
Jason TardioPresident and Chief Operating Officer
Inderpal SinghGeneral Counsel
Jessica BreuVice President Investor Relations and Communications
Chitrang DavéChief Data and Digital Officer
Hella KohlhofCo-Founder, Chief Scientific Officer
Jaa RobersonChief People Officer
Michael A. PanzaraChief Medical Officer
Patrick WalshChief Business Officer
Werner GladdinesChief Development Officer

Board

DirectorRole
Michael W. BonneyChair
Barclay Buck PhillipsIndependent Director
Elena RidloffIndependent Director
Erik LundgrenChief Executive Officer, Director
Jon CongletonIndependent Director
Jörg NeermannIndependent Director
Richard RudickIndependent Director
Simona SkerjanecIndependent Director
Thor NagelDirector

Events

Calls

CallWhenStatus
Immunic (NASDAQ:IMUX) Q3 2024 Earnings CallThu, Nov 07, 2024 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q2 2024 Earnings CallThu, Aug 08, 2024 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q1 2024 Earnings CallWed, May 08, 2024 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q4 2023 Earnings CallThu, Feb 22, 2024 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q3 2023 Earnings CallTue, Nov 14, 2023 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q2 2023 Earnings CallThu, Aug 03, 2023 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q1 2023 Earnings CallThu, May 11, 2023 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q4 2022 Earnings CallThu, Feb 23, 2023 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q3 2022 Earnings CallThu, Nov 03, 2022 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q2 2022 Earnings CallThu, Aug 04, 2022 · 8:00 AM ETReplay
All 13 calls
CallWhenStatus
Immunic (NASDAQ:IMUX) Q1 2022 Earnings CallTue, May 10, 2022 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q4 2021 Earnings CallThu, Feb 24, 2022 · 8:00 AM ETReplay
Immunic (NASDAQ:IMUX) Q3 2021 Earnings CallThu, Nov 04, 2021 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 13, 2026 · Before open−3.5%
Q2 2026Aug 11, 2026 · Before open0.0%
Q1 2026May 13, 2026 · Before open+8.8%
Q4 2025Feb 26, 2026+12.1%
Q3 2025Nov 13, 2025 · Before open−6.2%
Q2 2025Aug 7, 2025 · Before open−7.9%
Q1 2025May 15, 2025−1.6%
Q4 2024Mar 31, 2025 · Before open−9.2%
Q3 2024Nov 7, 2024 · Before open0.0%
Q2 2024Aug 8, 2024 · Before open+14.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · Before open−8.0%
Q4 2023Feb 22, 2024 · Before open−4.7%
Q3 2023Nov 14, 2023 · Before open+2.2%
Q2 2023Aug 3, 2023 · Before open−1.4%
Q1 2023May 11, 2023 · Before open+1.7%
Q4 2022Feb 23, 2023 · Before open+4.2%
Q3 2022Nov 3, 2022 · Before open−7.6%
Q2 2022Aug 4, 2022 · Before open+23.1%
Q1 2022May 10, 2022 · Before open+5.4%
Q4 2021Feb 24, 2022 · Before open−9.2%

Open Events

Decks

DeckKindSlidesDate
Investor Day (November 2026)Investor day56 slidesNov 5, 2026
Investor Presentation (November 2026)Investor deck47 slidesNovember 2026
Investor Presentation (October 2026)Investor deck40 slidesOctober 2026
Investor Day (September 2026)Investor day58 slidesSep 9, 2026
Investor Presentation (September 2026)Investor deck35 slidesSeptember 2026
Investor Presentation (July 2026)Investor deck35 slidesJul 14, 2026
EFMC-ACSMEDI MedChem Frontiers 2026Conference18 slidesJun 25, 2026
UEG Week Berlin 2025Conference11 slidesOct 6, 2025
41st Congress of ECTRIMS 2025Conference13 slidesSep 25, 2025
Investor Presentation (August 2025)Investor deck72 slidesAug 7, 2025
All 78 decks
DeckKindSlidesDate
Technical Presentation (May 2025)Technical22 slidesMay 28, 2025
Investor Presentation (April 2025)Investor deck44 slidesApr 30, 2025
Corporate Update (February 2025)Corporate update15 slidesFeb 20, 2025
Investor Presentation (January 2025)Investor deck73 slidesJan 13, 2025
Q3 2024 Earnings PresentationEarnings19 slidesNov 7, 2024
Corporate Update (October 2024)Corporate update16 slidesOct 22, 2024
Investor Day (September 2024)Investor day85 slidesSep 10, 2024
Technical Presentation (September 2024)Technical22 slidesSep 10, 2024
Technical Presentation (September 2024)Technical25 slidesSep 10, 2024
Q2 2024 Earnings PresentationEarnings17 slidesAug 8, 2024
Q1 2024 Earnings PresentationEarnings17 slidesMay 8, 2024
Technical Presentation (March 2024)Technical15 slidesMar 28, 2024
FY2023 Earnings PresentationEarnings19 slidesFeb 22, 2024
Q3 2023 Earnings PresentationEarnings20 slidesNov 14, 2023
Technical Presentation (October 2023)Technical34 slidesOct 10, 2023
Q2 2023 Earnings PresentationEarnings18 slidesAug 3, 2023
Q1 2023 Earnings PresentationEarnings18 slidesMay 11, 2023
Technical Presentation (May 2023)Technical61 slidesMay 4, 2023
Corporate Update (April 2023)Corporate update29 slidesApr 5, 2023
FY2022 Earnings PresentationEarnings20 slidesFeb 23, 2023
Technical Presentation (February 2023)Technical65 slidesFeb 9, 2023
Technical Presentation (February 2023)Technical73 slidesFeb 9, 2023
Technical Presentation (November 2022)Technical58 slidesNov 17, 2022
Q3 2022 Earnings PresentationEarnings18 slidesNov 3, 2022
ECTRIMS 2022Conference16 slidesOct 27, 2022
Technical Presentation (September 2022)Technical29 slidesSep 20, 2022
Technical Presentation (September 2022)Technical57 slidesSep 20, 2022
Q2 2022 Earnings PresentationEarnings24 slidesAug 4, 2022
3rd B & T Cell-Mediated Autoimmune Disease Drug Development Summit (July 2022)Conference29 slidesJul 28, 2022
16th World Immune Regulation Meeting 2022Conference14 slidesJul 9, 2022
Corporate Update (June 2022)Corporate update27 slidesJun 2, 2022
Corporate Update (June 2022)Corporate update29 slidesJun 2, 2022
Q1 2022 Earnings PresentationEarnings21 slidesMay 10, 2022
Corporate Update (May 2022)Corporate update57 slidesMay 10, 2022
FY2021 Earnings PresentationEarnings33 slidesFeb 24, 2022
Investor Presentation (January 2022)Investor deck56 slidesJan 10, 2022
Technical Presentation (December 2021)Technical99 slidesDec 14, 2021
Q3 2021 Earnings PresentationEarnings24 slidesNov 4, 2021
Technical Presentation (July 2021)Technical55 slidesJul 12, 2021
Investor Presentation (July 2021)Investor deck33 slidesJul 1, 2021

Open Decks

Financings

RaiseDate
Private placement of pre-funded warrants and warrants
Closed: US$200M raised · US$0.873 a share · Warrants at US$0.873 · Leerink Partners +6
Dealers: Leerink Partners (lead), Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities, Brookline Capital Markets
Buyers: BVF Partners L.P. (led the financing); Aberdeen Investments; Avidity Partners; Coastlands Capital; EcoR1 Capital; Janus Henderson Investors; OrbiMed; RA Capital Management; TCGX; Trails Edge Capital Partners; Vivo Capital; Woodline Partners LP
Use of proceeds: To fund clinical trials and operations and for general corporate purposes
Feb 17, 2026
Public offering of pre-funded warrants, Series A warrants and Series B warrants
Closed: US$65M raised · US$0.7499 a share · Series A Warrants exercisable until December 31, 2025; Series B Warrants exercisable… · Leerink Partners +3
Dealers: Leerink Partners (lead), B. Riley Securities, Brookline Capital Markets, a division of Arcadia Securities, LLC, William Blair & Company, L.L.C.
Buyers: BVF Partners (co-led the financing); Coastlands Capital (co-led the financing); Aberdeen Investments; Adage Capital Partners LP; Janus Henderson Investors
Use of proceeds: Fund clinical trials and operations and general corporate purposes
Jun 3, 2025
Registered direct offering of shares of common stock
Closed: US$5.1M raised · US$0.9 a share · Titan Partners Group, a division of American Capital Partners
Dealers: Titan Partners Group, a division of American Capital Partners (lead)
Buyers: Aberdeen Investments
Use of proceeds: Fund clinical trials and operations and other general corporate purposes
Apr 10, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as VITAL THERAPIES INC. Priced at US$12.00 a share on Apr 16, 2014.

Price
US$12.00 a share
Shares offered
4,500,000 shares of common stock
Offering size
US$54 million
Underwriters
BofA Merrill Lynch, Credit Suisse, William Blair, Canaccord Genuity · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJul 22, 2013
Filed publiclyOct 11, 2013
Amended 7 timesNewest Apr 9, 2014
Shares registered with an exchangeNov 15, 2013
Declared effective by the SECApr 16, 2014
Final prospectus, with the priceApr 17, 2014

Filings

FilingFiled
424B4 · ProspectusApr 17, 2014
EFFECT · Notice that a registration is effectiveApr 16, 2014
FWP · Free writing prospectusApr 16, 2014
CORRESP · Letter to the SECApr 14, 2014
CORRESP · Letter to the SECApr 14, 2014
S-1/A · Registration statement, amendedApr 9, 2014
FWP · Free writing prospectusApr 9, 2014
CORRESP · Letter to the SECApr 8, 2014
UPLOAD · Letter from the SECApr 7, 2014
S-1/A · Registration statement, amendedApr 7, 2014
All 35 filings
FilingFiled
CORRESP · Letter to the SECApr 3, 2014
CORRESP · Letter to the SECApr 3, 2014
S-1/A · Registration statement, amendedApr 3, 2014
UPLOAD · Letter from the SECApr 2, 2014
S-1/A · Registration statement, amendedMar 11, 2014
FWP · Free writing prospectusNov 20, 2013
CERTNAS · Nasdaq's certificate of listingNov 19, 2013
CORRESP · Letter to the SECNov 18, 2013
CORRESP · Letter to the SECNov 18, 2013
8-A12B · Registration of shares for listing on an exchangeNov 15, 2013
S-1/A · Registration statement, amendedNov 15, 2013
S-1/A · Registration statement, amendedNov 6, 2013
CORRESP · Letter to the SECNov 1, 2013
CORRESP · Letter to the SECOct 30, 2013
S-1/A · Registration statement, amendedOct 30, 2013
CORRESP · Letter to the SECOct 25, 2013
UPLOAD · Letter from the SECOct 24, 2013
CORRESP · Letter to the SECOct 11, 2013
S-1 · Registration statementOct 11, 2013
UPLOAD · Letter from the SECSep 12, 2013
DRSLTR · Letter to the SEC with a draftAug 30, 2013
DRS/A · Draft registration statement, amendedAug 30, 2013
UPLOAD · Letter from the SECAug 21, 2013
DRSLTR · Letter to the SEC with a draftJul 22, 2013
DRS · Draft registration statementJul 22, 2013

Open IPO · From the cover of the final prospectus (424B4) filed Apr 17, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000006.00K
Cost of revenue168.0K134.0K111.0K77.0K85.0K39.0K50.0K15.0K998.0K206
Gross profit-168.0K-134.0K-111.0K-77.0K-85.0K-39.0K-50.0K-15.0K-998.0K5.79K
Research and development82.0M80.0M83.2M71.3M61.1M38.6M22.5M9.60M39.3M30.0M
Selling, general and administrative21.2M18.0M16.0M15.3M13.3M10.3M14.5M13.6M13.3M11.2M
Operating income-103.2M-98.1M-99.2M-119.5M-91.7M-49.0M-37.0M-12.0M-52.7M-41.3M
Depreciation and amortization168.0K134.0K111.0K77.0K85.0K39.0K50.0K15.0K998.0K1.81M
EBITDA-103.1M-97.9M-99.1M-119.4M-91.6M-48.9M-37.0M-12.0M-51.7M-39.5M
Interest expense1.04M85.0K58.0K107.0K000
Income before tax-97.2M-100.5M-93.6M-120.4M-92.9M-44.0M-34.9M-41.5M-52.1M-41.0M
Income tax0-100.5M33.9M-151.0K-58.0K-107.0K549.0K-577.0K-1.81M
Net income-97.2M-100.5M-93.6M-120.4M-92.9M-44.0M-34.9M-11.5M-52.1M-41.0M
Earnings per share, basic-0.62-1.00-2.11-3.78-3.93-2.81-4.52-13.63-1.31-1.31
Earnings per share, diluted-0.62-1.00-2.11-3.78-3.93-2.81-4.52-13.63-1.31-1.31

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents15.5M35.7M46.7M106.7M86.9M127.5M29.4M13.1M56.9M60.0M
Short-term investments09.63M000
Receivables4.12M684.0K703.0K296.0K2.15M295.0K408.0K191.0K541.5K
Inventory5.61M-2.15M3.42M-408.0K-191.0K00
Current assets22.9M39.3M52.5M125.9M105.0M133.7M32.2M13.3M58.1M61.5M
Property, plant and equipment608.0K545.0K466.0K294.0K152.0K203.0K80.0K40.0K2.15M2.50M
Goodwill033.0M33.0M33.0M000
Total assets24.1M40.9M54.3M127.8M139.1M167.9M66.0M13.4M60.4M64.0M
Accounts payable10.1M7.85M5.10M4.28M3.75M3.70M2.42M1.40M1.05M780.0K
Current liabilities30.6M22.2M24.7M13.1M11.4M8.40M7.07M1.92M10.3M5.48M
Long-term debt00
Total debt684.0K1.00M1.33M1.56M992.0K976.0K520.0K37.2M
Total liabilities30.7M22.4M25.4M14.1M12.0M9.08M7.59M1.92M10.3M5.58M
Shareholders' equity-6.67M18.4M28.9M113.7M127.1M158.8M58.4M-25.7M-13.3M58.4M
Shares outstanding15.9M90.2M45.2M39.3M26.3M21.2M10.7M847.0K42.4M32.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-85.8M-84.8M-70.8M-65.1M-83.2M-46.1M-28.5M-9.74M-40.4M-35.8M
Capital spending-161.0K-264.0K-334.0K-112.0K-67.0K-146.0K-55.0K-32.0K-685.0K-556.0K
Free cash flow-86.0M-85.0M-71.2M-65.3M-83.3M-46.3M-28.6M-9.77M-41.1M-36.3M
Cash from investing-161.0K-264.0K9.46M-9.74M-67.0K-146.0K10.5M-32.0K-678.0K-21.0K
Cash from financing65.6M74.5M1.03M95.8M42.8M144.4M34.9M19.3M38.0M12.4M
Dividends paid00
Share buybacks182.0K77.0K129.0K182.0K92.0K144.4M34.9M4.00K38.0M12.4M
Change in cash-20.2M-11.0M-60.1M19.9M-40.6M98.1M16.3M8.57M-3.09M-23.4M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
8-K · Current reportNov 13, 2026ResultsSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 2, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansOct 1, 2026Offer documentSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
All 837 filings
FilingDateTypeFiled with
8-K · Current reportSep 11, 2026Management or board changeSEC
8-K · Current reportSep 9, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 12, 2026Offer documentSEC
8-K · Current reportAug 11, 2026ResultsSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 10, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 4, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2026Big-stake noticeSEC
8-K · Current reportJul 14, 2026Current reportSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
8-K · Current reportJul 6, 2026Management or board changeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
8-K · Current reportJun 29, 2026Management or board changeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 1, 2026Insider tradeSEC
DEF 14A · Proxy statementMay 29, 2026Meeting noticeSEC
8-K · Current reportMay 28, 2026Current reportSEC
8-K · Current reportMay 27, 2026Management or board changeSEC
3 · Initial statement of ownershipMay 19, 2026Insider tradeSEC
8-K · Current reportMay 19, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 13, 2026ResultsSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeMay 6, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMay 5, 2026Other filingsSEC
CORRESP · Letter to the SECMay 1, 2026Other filingsSEC
S-3/A · Registration statement, amendedApr 30, 2026Offer documentSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
8-K · Current reportApr 28, 2026Management or board changeSEC
8-K · Current reportApr 23, 2026Current reportSEC
10-K/A · Annual report, amendedApr 22, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeApr 17, 2026Big-stake noticeSEC
8-K · Current reportApr 14, 2026Meeting outcomeSEC
8-K · Current reportApr 10, 2026Management or board changeSEC
S-8 · Registration statement for employee plansApr 9, 2026Offer documentSEC
UPLOAD · Letter from the SECApr 6, 2026Other filingsSEC
S-3 · Registration statementApr 2, 2026Offer documentSEC
8-K · Current reportApr 1, 2026Current reportSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
8-K · Current reportMar 31, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeMar 4, 2026Big-stake noticeSEC
DMar 4, 2026Other filingsSEC
DEF 14A · Proxy statementMar 2, 2026Meeting noticeSEC
3 · Initial statement of ownershipFeb 27, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 27, 2026Insider tradeSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 24, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 24, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 20, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementFeb 20, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 20, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 19, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
8-K · Current reportFeb 13, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 2, 2026Big-stake noticeSEC
8-K · Current reportJan 6, 2026Current reportSEC
8-K · Current reportJan 5, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeDec 8, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
8-K · Current reportSep 25, 2025Current reportSEC
S-8 · Registration statement for employee plansAug 27, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 8, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2025Big-stake noticeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
8-K · Current reportJul 11, 2025Management or board changeSEC
8-K · Current reportJun 27, 2025Current reportSEC
4/A · Change in ownership, amendedJun 20, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 20, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 20, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 20, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
8-K · Current reportJun 4, 2025Management or board changeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
8-K · Current reportMay 30, 2025Material contractSEC
424B5 · ProspectusMay 30, 2025Offer documentSEC
424B5 · ProspectusMay 28, 2025Offer documentSEC
8-K · Current reportMay 28, 2025Current reportSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportApr 30, 2025Current reportSEC
DEFA14A · Additional proxy materialApr 22, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2025Meeting noticeSEC
424B5 · ProspectusApr 9, 2025Offer documentSEC
8-K · Current reportApr 9, 2025Material contractSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportFeb 20, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
8-K · Current reportDec 18, 2024Management or board changeSEC
4/A · Change in ownership, amendedDec 9, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
8-K · Current reportOct 22, 2024Current reportSEC
8-K · Current reportSep 10, 2024Current reportSEC
8-K · Current reportSep 3, 2024Material contractSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
4 · Change in ownershipJul 24, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 24, 2024Insider tradeSEC
8-K · Current reportJul 24, 2024Management or board changeSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 12, 2024Insider tradeSEC
8-K · Current reportJul 9, 2024Management or board changeSEC
S-8 · Registration statement for employee plansJul 2, 2024Offer documentSEC
8-K · Current reportJun 12, 2024Meeting outcomeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
424B5 · ProspectusJun 10, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 3, 2024Other filingsSEC
CORRESP · Letter to the SECMay 29, 2024Other filingsSEC
S-3/A · Registration statement, amendedMay 24, 2024Offer documentSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveMay 1, 2024Other filingsSEC
424B3 · ProspectusApr 30, 2024Offer documentSEC
CORRESP · Letter to the SECApr 26, 2024Other filingsSEC
DEF 14A · Proxy statementApr 23, 2024Meeting noticeSEC
8-K · Current reportMar 8, 2024Meeting outcomeSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Immunic, Inc.’s releases · as of Feb 17, 2026

Common shares
13,644,467
Fully diluted
13,644,467

Fully diluted

LineShares
Common shares13,644,467

Warrants and options

Lot
Warrants · US$0.87 · expiry not stated
Warrants · expiry not stated

Share count over time

CountShares
Nov 22, 202613,644,467

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
abrdn1.09M6.9%US$10.1MSep 30, 2026
Bvf Inc765K4.8%US$7.12MSep 30, 2026
Morgan Stanley704K4.4%US$6.55MSep 30, 2026
Seven Fleet Capital Management LP687K4.3%US$3.66MSep 30, 2026
Millennium681K4.3%US$6.33MSep 30, 2026
Avidity Partners Management LP670K4.2%US$6.23MSep 30, 2026
Vanguard660K4.2%US$6.14MSep 30, 2026
Braidwell LP645K4.1%US$6MSep 30, 2026
Laurion Capital Management LP610K3.8%US$5.68MSep 30, 2026
Orbimed Advisors LLC476K3.0%US$4.42MSep 30, 2026
All 78 holders
HolderSharesOf the companyValueAs of
Woodline Partners LP472K3.0%US$4.39MSep 30, 2026
Omega Fund Management, LLC430K2.7%US$4MSep 30, 2026
Marshall Wace, LLP359K2.3%US$3.34MSep 30, 2026
Nantahala Capital Management, LLC251K1.6%US$2.33MSep 30, 2026
Propel Bio Management, LLC237K1.5%US$2.2MSep 30, 2026
Jane Street214K1.3%US$1.99MSep 30, 2026
UBS184K1.2%US$1.71MSep 30, 2026
Ikarian Capital, LLC182K1.1%US$1.7MSep 30, 2026
Geode Capital172K1.1%US$1.6MSep 30, 2026
Qube Research & Technologies Ltd148K0.93%US$1.37MSep 30, 2026
Adage Capital Partners Gp, L.L.C.140K0.88%US$1.3MSep 30, 2026
Citadel130K0.82%US$1.21MSep 30, 2026
BlackRock126K0.79%US$1.17MSep 30, 2026
Susquehanna111K0.70%US$1.03MSep 30, 2026
State Street83,8590.53%US$780KSep 30, 2026
Renaissance Technologies71,3300.45%US$663KSep 30, 2026
683 Capital Management, LLC65,0000.41%US$605KSep 30, 2026
Boothbay Fund Management, LLC46,8200.29%US$435KSep 30, 2026
Schonfeld Strategic Advisors LLC45,5990.29%US$424KSep 30, 2026
Squarepoint Ops LLC42,2830.27%US$393KSep 30, 2026
Two Sigma37,6710.24%US$350KSep 30, 2026
Engineers Gate Manager LP36,6000.23%US$340KSep 30, 2026
Quadrature Capital Ltd31,0580.20%US$289KSep 30, 2026
Simplify Asset Management Inc.30,7250.19%US$286KSep 30, 2026
Northern Trust30,7200.19%US$286KSep 30, 2026
Birchview Capital, LP21,9170.14%US$204KSep 30, 2026
Axq Capital, LP21,0090.13%US$195KSep 30, 2026
Graham Capital Management, L.P.19,7220.12%US$183KSep 30, 2026
Alps Advisors Inc17,6940.11%US$165KSep 30, 2026
American Century17,5230.11%US$163KSep 30, 2026
LPL Financial LLC17,0120.11%US$158KSep 30, 2026
Catalyst Funds Management Pty Ltd16,3390.10%US$152KSep 30, 2026
XTX Topco Ltd15,2400.10%US$142KSep 30, 2026
Spark Investment Management LLC11,6000.07%US$108KSep 30, 2026
Mml Investors Services, LLC11,4870.07%US$107KSep 30, 2026
Point72 Asset Management, L.P.10,8060.07%US$100KSep 30, 2026
Prelude Capital Management, LLC10,7790.07%US$100KSep 30, 2026
Bank of America10,4720.07%US$97,390Sep 30, 2026
Strategies Wealth Advisors, LLC10,0000.06%US$93,000Sep 30, 2026
China Universal Asset Management Co., Ltd.7,8000.05%US$69,498Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund399K2.5%US$6.13MJun 30, 2026
Vanguard Extended Market Index Fund159K1.0%US$2.45MJun 30, 2026
Fidelity Extended Market Index Fund63,0100.40%US$943KMay 31, 2026
iShares Micro-Cap ETF46,2430.29%US$711KJun 30, 2026
Simplify Propel Opportunities ETF30,7250.19%US$472KJun 30, 2026
Fidelity Total Market Index Fund29,2530.18%US$438KMay 31, 2026
Fidelity Series Total Market Index Fund17,8080.11%US$266KMay 31, 2026
Fidelity Nasdaq Composite Index Fund9,8390.06%US$147KMay 31, 2026
Schwab Total Stock Market Index Fund8,5000.05%US$119KJul 31, 2026
Fidelity ZERO Total Market Index Fund8,0370.05%US$112KJul 31, 2026
All 19 holders
HolderSharesOf the companyValueAs of
Vanguard Institutional Total Stock Market Index Fund6,9930.04%US$107KJun 30, 2026
Vanguard Balanced Index Fund6,2320.04%US$95,786Jun 30, 2026
Fidelity ZERO Extended Market Index Fund5,1540.03%US$72,001Jul 31, 2026
1290 VT Micro Cap Portfolio3,1210.02%US$47,970Jun 30, 2026
Fidelity Flex Small Cap Index Fund2,2070.01%US$30,832Jul 31, 2026
Victory Extended Market Index Fund1,556<0.01%US$21,737Jul 31, 2026
VIP Extended Market Index Portfolio866<0.01%US$13,310Jun 30, 2026
VIP Total Market Index Portfolio297<0.01%US$4,565Jun 30, 2026
Total Stock Market Index Trust277<0.01%US$4,257Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Commodore Capital LP9.90%1.51MJun 30, 2026Schedule 13G
Aberdeen Group plc7.99%1.09MSep 30, 2026Schedule 13G
Nantahala Capital Management, LLC7.47%1.08MJun 30, 2026Schedule 13G
Laurion Capital Management LP6.06%840KJun 30, 2026Schedule 13G
Morgan Stanley5.20%704KSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Mark N Lampert
Other companies: Kymera Therapeutics, Inc. (Director · Since at least Jan 11, 2023); Olema Pharmaceuticals, Inc. (Director · Since at least Jun 10, 2022); MoonLake Immunotherapeutics (Director · Since at least Apr 5, 2022); Rain Oncology Inc (Director · Nov 8, 2022 – Jan 25, 2024 · Past); CTi Biopharma Corp (Director · Aug 9, 2022 – Jun 26, 2023 · Past)
Director · Since at least Feb 17, 2026
Elena Ridloff
Other companies: Sionna Therapeutics, Inc. (CFO and CBO · Since at least Feb 6, 2025); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020); ACADIA Pharmaceuticals Inc. (EVP and CFO · Jan 6, 2021 – Apr 29, 2021 · Past)
Director · Since at least Aug 6, 2026
Muneer A Satter
Other companies: Annexon, Inc. (Director · Since at least Jul 23, 2020); Rein Therapeutics, Inc. (See Remarks, Director · Jun 8, 2020 – Jan 8, 2021 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Jun 18, 2019 · Past); Akebia Therapeutics, Inc. (Director · Mar 19, 2014 – Jun 14, 2018 · Past)
Director · Apr 16, 2014 – Sep 13, 2018 · Past
Tamar D Howson
Other companies: Cue Biopharma, Inc. (Director · Sep 17, 2020 – Jan 3, 2023 · Past); Lite Strategy, Inc. (Director · Jul 1, 2019 – Sep 29, 2023 · Past); VivoSim Labs, Inc. (Director · Jul 26, 2018 – Jul 26, 2018 · Past)
Director · Since at least Oct 11, 2019
Jon Congleton
Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Mineralys Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Feb 9, 2023)
Director · Since at least Mar 27, 2026
Jon Congleton
Other companies: Mineralys Therapeutics, Inc. (Chief Executive Officer · Since at least Oct 2, 2026); Avalyn Pharma Inc. (Since at least Apr 6, 2026)
Independent Director · Since at least May 13, 2026
Michael A. Panzara
Other companies: LeonaBio, Inc. (Director · Since at least Mar 18, 2022); Wave Life Sciences Ltd. (See Remarks · Feb 1, 2021 – Jul 25, 2022 · Past)
Chief Medical Officer · Since at least Apr 24, 2026
Randolph C Steer
Other companies: Capstone Holding Corp. (President · Jan 17, 2011 – Jan 17, 2011 · Past); Bio-Techne Corp (Director · Oct 28, 2010 – Oct 26, 2023 · Past)
Director · Apr 16, 2014 – May 23, 2017 · Past
Simona Skerjanec
Other companies: Atrium Therapeutics, Inc. (Director · Since at least Nov 10, 2025); Avidity Biosciences, Inc (Director · Since at least May 14, 2024)
Director · Since at least Jul 22, 2024
Glenn Whaley
Other companies: Pernix Therapeutics Holdings Inc (VP of Fin, PAO & Controller · Nov 29, 2017 – Aug 8, 2018 · Past)
Chief Financial Officer · Since at least Dec 1, 2019
All 30 people
PersonSeat
Monika Maria Toernsen
Other companies: Passage Bio, Inc. (Chief Commercial Officer · Jul 19, 2021 – Sep 15, 2022 · Past)
Director · Since at least Jul 5, 2022
Aron SternChief Administrative Officer · May 13, 2016 – Jul 1, 2018 · Past
Barclay A PhillipsDirector · Since at least Jun 5, 2025
Barclay Buck PhillipsIndependent Director · Since at least Nov 5, 2026
Chitrang DavéChief Data and Digital Officer · Since at least Sep 1, 2026
Daniel VittDirector · Since at least Apr 12, 2019
Duane NashExecutive Chairman, Director · Since at least May 12, 2022
Erik LundgrenChief Executive Officer, Director · Since at least May 22, 2026
Hella KohlhofCo-Founder, Chief Scientific Officer · Since at least Oct 29, 2026
Inderpal SinghGeneral Counsel · Since at least Nov 4, 2026
Jaa RobersonChief People Officer · Since at least Oct 19, 2026
Jason TardioPresident and Chief Operating Officer · Since at least Nov 2, 2026
Jessica BreuVice President Investor Relations and Communications · Since at least Oct 29, 2026
Jörg NeermannIndependent Director · Since at least Nov 5, 2026
Manfred GroeppelChief Operating Officer · Apr 12, 2019 – Mar 1, 2021 · Past
Michael W. BonneyChair · Since at least Aug 11, 2026
Patrick WalshChief Business Officer · Since at least Nov 2, 2026
Richard RudickIndependent Director · Since at least Apr 26, 2023
Thor NagelDirector · Since at least May 13, 2026
Werner GladdinesChief Development Officer · Since at least Jun 5, 2025

Open People

Log in to ask 6ix AI your own questions about Immunic, Inc.